
Valneva SE (VALN) Stock Forecast & Price Target
Valneva SE (VALN) Analyst Ratings
Bulls say
Valneva SE demonstrates a positive outlook due to the increased assumptions for the commercial uptake of its vaccine candidate VLA15 in Europe, aligning expectations with existing U.S. market projections. Additionally, the company has reported strong immune responses after administering a third yearly booster of VLA15, which bodes well for its future performance in the market. Although there was an unexpected suspension of the Ixchiq vaccine by the FDA, the overall earnings remained in line with expectations, indicating stability amidst regulatory challenges.
Bears say
Valneva SE faces several significant risks that contribute to a negative outlook, primarily related to potential clinical and regulatory setbacks that could hinder its vaccine development efforts and market acceptance. Recent safety concerns regarding its Ixchiq vaccine have raised doubts about its competitiveness against rivals like Bavarian Nordic's chikungunya vaccine, which may further impact Valneva's market position, particularly in Europe. Additionally, the decision to eliminate US Ixchiq sales from financial models reflects expectations of limited commercial uptake, underscoring concerns about future revenue generation and profitability.
This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.
Valneva SE (VALN) Analyst Forecast & Price Prediction
Start investing in Valneva SE (VALN)
Order type
Buy in
Order amount
Est. shares
0 shares